Search Orphan Drug Designations and Approvals
-
Generic Name: | betibeglogene autotemcel | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Zynteglo | |||||||||||||
Date Designated: | 03/18/2013 | |||||||||||||
Orphan Designation: | Treatment of B-thalassemia major and intermedia | |||||||||||||
Orphan Designation Status: | Designated/Approved | |||||||||||||
Sponsor: |
bluebird bio, Inc. 60 Binney Street Cambridge, Massachusetts 02142 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
|||||||||||||
Marketing approved: |
||||||||||||||
1 | Generic Name: | betibeglogene autotemcel |
---|---|---|
Trade Name: | Zynteglo | |
Marketing Approval Date: | 08/17/2022 | |
Approved Labeled Indication: | Treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell (RBC) transfusions | |
Exclusivity End Date: | TBD | |
-